CDK4/6 inhibitors for metastatic breast cancer
14 Oct 2016
CDK4/6 inhibitors for metastatic breast cancer
TRAIL induced apoptosis for cancer stem cells
Carcinoid syndrome
Who should receive combination therapy for ER positive breast cancer?
Drug repurposing of propranolol
ESMO 2016 conference highlights
Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody:
LUME study of nintedanib finds improved PFS, but no overall survival boost
Left versus right sided GI tumour response in the CRYSTAL trial
Oncolytic virotherapy using coxsackie virus
Results of the Activ8 trial of novel immunotherapy motolimod